GlobeNewsWire
29 Jun 2026, 17:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Grail's NHS-Galleri trial failed to observe the primary endpoint of statistically significant Stage III-IV cancer reduction. — The failure of a primary clinical endpoint for a flagship product typically destroys the core investment thesis and leads to massive valuation write-downs.
-1.00Grail shares experienced a single-day collapse of 50.55%, losing $51.32 per share on February 20, 2026. — Such a severe price correction indicates a total loss of market confidence and high volatility for the security.
-0.80A securities class action lawsuit has been filed alleging that Grail management provided misleading disclosures and withheld top-line data from analysts. — Litigation creates long-term legal liabilities, management distraction, and further erodes investor trust in company guidance.
-0.50Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a securities class action lawsuit following a 50.55% stock collapse and failure to meet a primary trial endpoint.
The company is mentioned as being subject to a filed class action lawsuit.
The company is mentioned as being subject to a pending securities class action.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
2h ago
